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Abstract
Diabetic nephropathy is the leading cause of end-stage
renal disease in Western countries, but only a portion of
diabetic patients develop diabetic nephropathy. Dyslip-
idemia represents an important aspect of the metabolic
imbalance in diabetic patients. In this study, we ad-
dressed the impact of combined hyperlipidemia and
hyperglycemia on renal pathology. Kidneys from wild-
type (WT) or LDL receptor-deficient BALB/cBy mice
(BALB.LDLR–/–) were examined at 22 weeks of age. Dia-
betes was induced by administration of streptozotocin
and mice were randomly assigned to either standard
chow or Western diet. Chow fed BALB.LDLR–/– mice did
not demonstrate renal abnormalities, whereas BALB.
LDLR–/– mice fed a Western diet showed occasional glo-
merular and tubulointerstitial foam cells. Diabetic WT mice
had modestly increased glomerular cellularity and extra-
cellular matrix. Hyperlipidemic and diabetic BALB.LDLR–/–
mice exhibited an increase in glomerular cellularity and
extracellular matrix, accumulation of glomerular and tubu-
lointerstitial foam cells and mesangial lipid deposits. The
tubular epithelium demonstrated pronounced lipid in-
duced tubular degeneration with increased tubular epithe-
lial cell turnover. Hyperlipidemia and hyperglycemia seem
to act synergistically in inducing renal injury in the
BALB.LDLR–/– mouse. This model of diabetic nephropathy
is unique in its development of tubular lesions and may
represent a good model for hyperlipidemia-exacerbated
diabetic nephropathy.
Copyright © 2004 S. Karger AG, Basel
Introduction
The prevalence of type II diabetes mellitus is rising in
all Western countries and diabetic nephropathy has be-
come the leading cause for end-stage renal disease
(ESRD) in the US, accounting for 33% of patients on kid-
ney replacement therapy in 1999 [1]. In diabetic patients,
hyperglycemia has been established as a major risk factor
for renal failure [2, 3] leading to thickening of the glomer-
ular and tubular basement membranes and expansion of
extracellular matrix, and eventually to the development
of glomerulosclerosis and renal failure. However, since
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only a portion of diabetic patients develop clinically
apparent nephropathy [4–7], it is likely that factors other
than hyperglycemia influence the incidence and progres-
sion of diabetic nephropathy.
Hyperlipidemia represents an established risk factor
for the development of atherosclerosis and vascular dis-
ease in diabetes mellitus [8]. With regard to renal disease,
animal studies indicate that hyperlipidemia alone can
induce renal injury characterized by increased glomerular
cellularity, accumulation of mesangial matrix and lipid
deposition in the mesangium [9–14]. Nevertheless, the
influence of hyperlipidemia on the initiation and progres-
sion of diabetic nephropathy remains incompletely un-
derstood. In humans, studies of patients with early onset
insulin-dependent diabetes mellitus and nephropathy
have established a relationship between hyperlipidemia
and diabetic nephropathy and have provided some evi-
dence that hyperlipidemia may accelerate the progression
of diabetic nephropathy [15, 16]. In patients with type II
diabetes the current data are less clear, with some studies
showing a correlation between plasma lipids and progres-
sion of diabetic nephropathy [17, 18] while others could
not find an association between hyperlipidemia and dia-
betic nephropathy [19, 20]. A few studies with lipid-low-
ering agents report beneficial effects of these drugs on dia-
betic nephropathy with decrease in proteinuria and slow-
ing of the decline in glomerular filtration rate (GFR) [21–
23]. However, the mechanism by which hyperglycemia
and hyperlipidemia exert their harmful effect on the kid-
ney remains largely unknown, and animal models suitable
for the investigation of diabetic nephropathy have major
limitations. Currently, the most common animal model
for diabetic nephropathy of type I diabetes mellitus
involves the use of the islet toxin streptozotocin (STZ).
Animals with STZ-induced hyperglycemia display renal
pathology mostly in the glomeruli, while the tubulointer-
stitium and vasculature are generally spared and animals
do not progress to renal failure. Animal models that more
closely reproduce clinical and pathological features of
human disease are needed in order to investigate the dif-
ferent sequelae of the metabolic disturbances in diabetes
mellitus, especially the influence of hyperlipidemia. Here
we describe early renal pathology in a new rodent model
of genetic and alimentary hyperlipidemia, the BALB.
LDLR–/– mouse. We report that these hyperlipidemic
mice, made diabetic by STZ treatment, display both glo-
merular and tubular pathology, and that hyperglycemia
and hyperlipidemia seem to act synergistically in the pro-
gression of renal disease.
Methods and Materials
Animal Study
Female BALB/cByJ (BALB) wild type and male C57BL/6J-
LDLrtmlHer (LDLR–/–) mice were obtained from Jackson Laboratory
(Bar Harbor, Me., USA). Mice deficient in the LDL receptor were
backcrossed for 8 generations onto the BALB/cByJ genetic back-
ground. After 8 generations of backcrossing less than 0.4% of
unlinked C57BL/6 genes are retained in the new CBy.129S7(B6)-
Ldlrtm1Her BALB.LDLR-deficient mice. After that, mice heterozy-
gous for the LDL receptor mutation were then intercrossed to pro-
duce mice homozygous for the disrupted LDL receptor (BALB.
LDLR–/–). Littermate controls with and without the LDL receptor
mutation were used in the study. All animals were maintained in the
animal care facility of the University of Washington in a tempera-
ture-controlled room (25°C) with fixed 12-hour light/dark cycle.
They had free access to food and water but food was removed 4 h
before collection of blood samples from the retro-orbital plexus or at
necropsy. Blood was collected in tubes containing 1 mM EDTA and
plasma was stored at –70°C until analysis.
Experimental Design
Female mice of BALB and BALB.LDLR–/– strains were used in
this study. Mice were initially maintained on pelleted rodent chow
(Wayne Rodent BLOX 8604, Teklad, Madison, Wisc., USA) and
randomly assigned to one of 4 treatment groups: rodent chow (n = 6
for BALB and n = 6 for BALB.LDLR–/–), rodent chow and STZ (n =
6 for BALB and n = 7 for BALB.LDLR–/–), Western diet (n = 7 for
BALB and n = 10 for BALB.LDLR–/–) and Western diet and STZ
(n = 6 for BALB and n = 13 for BALB.LDLR–/–). Rodent chow con-
tained 4% fat, 24% protein and 4.5% crude fiber. The Western diet
contained 21% fat and 0.15% cholesterol (TD 88137, Harlan Teklad
BLOX, Madison, Wisc., USA). Hyperglycemia was induced by intra-
peritoneal injection of the islet toxin STZ (STZ; 40 mg/kg body
weight) for 5 consecutive days at 7 and 9 weeks of age. Non-STZ
groups were injected with citrate buffer. At 12 weeks of age, diet
groups within STZ and citrate-treated mice were assigned to rodent
chow or Western diet. Diets were fed for 10 weeks. The study was
originally designed to evaluate disease in large extrarenal arterial ves-
sels; the opportunity to study morphologic changes in the kidney
developed after all the animals had been sacrificed.
The animal study was reviewed and approved by the Animal
Care and Use Committee of the University of Washington according
to the principles of laboratory animal care.
Analytical Procedures
Animals in this study were examined retrospectively so that avail-
ability of serum samples for evaluation of laboratory data was lim-
ited to the assays reported below.
Plasma glucose levels were measured colorimetrically (Trinder
Glucose 500 Diagnostic kit, Sigma, St. Louis, Mo., USA). Plasma
total cholesterol levels were determined using a colorimetric kit
(Diagnostic Chemicals Limited, Oxford, Conn., USA) with choles-
terol standards (Boehringer Mannheim, Indianapolis, Ind., USA).
Plasma triglyceride levels were determined colorimetrically follow-
ing the removal of free glycerol (Diagnostic kit #450032, Boehringer
Mannheim). Plasma BUN levels were assessed with a colorimetric
assay (Diagnostic kit #535-A, Sigma).
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Tissue Preparation and Histological Staining
Mice were sacrificed at 22 weeks of age by cervical dislocation
and whole animals were perfused with 10 ml of antioxidant buffer
(100 ÌM DTPA, 100 ÌM BHT, 0.1% ethanol in PBS, pH 7.4) via the
left ventricle. Kidneys were removed and fixed in 10% neutral buff-
ered formalin or in methyl Carnoy’s solution for histological exami-
nation and in half-strength Karnovsky’s solution (1% paraformalde-
hyde and 1.25% glutaraldehyde in 0.1 M sodium cacodylate buffer,
pH 7.0) for electron microscopy. Tissues for histology were processed
following standard protocols and cut into 2-Ìm sections for periodic
acid-methenamine silver (PAM) staining and into 4-Ìm sections for
hematoxylin-eosin (HE) staining, immunohistochemistry and
TUNEL staining.
Immunohistochemistry and TUNEL Staining
For immunohistochemistry 4-Ìm-thick tissue sections were depa-
raffinized in xylene and rehydrated through graded ethanol. Antigen
retrieval was performed by steam heating in Antigen Unmasking
Solution when necessary (Vector Laboratories, Burlingame, Calif.,
USA). Endogenous peroxidases were blocked by incubation with 3%
hydroxygen peroxide for 5 min and endogenous biotin was blocked
using the Avidin/Biotin blocking kit (Vector). Primary antibodies
were diluted in PBS containing 1% BSA (Sigma, St. Louis, Mo.,
USA) and slides were incubated for 1 h at room temperature. Sec-
tions were washed in PBS and then incubated with appropriate bio-
tinylated secondary antibodies. The ABC-Elite Reagent (Vector) was
utilized for signal amplification, and 3,3)-diaminobenzidine (DAB;
Sigma) with nickel enhancement was used as chromogen, resulting in
a black color product. Sections were counterstained with periodic
acid Schiff/methyl-green, dehydrated and coverslipped. Macro-
phages were detected using a rat anti-mouse MAC-2 antibody as pre-
viously described [24] (Cederlane, Ontario, Canada) and a mouse-
adsorbed anti-rat antibody was utilized as secondary anti-body (Vec-
tor Laboratories). A monoclonal mouse IgG2a antibody was used for
detection of mesangial ·-smooth muscle actin expression (as pre-
viously described [25]) (clone 1A4, DAKO, Carpinteria, Calif.,
USA). Here the secondary antibody was a monoclonal rat anti-mouse
IgG2a anti-body (Pharmingen, San Diego, Calif., USA). Cellular pro-
liferation was assessed using a mouse monoclonal anti-human PCNA
antibody [as previously described, 26] (Oncogene Research Products,
Cambridge, Mass., USA) with a monoclonal rat anti-mouse second-
ary antibody (Vector Laboratories).
TUNEL staining was performed using a TdT-FragEL DNA frag-
mentation detection kit (Oncogene Research Products) according to
the manufacturer’s instructions and as previously described in detail
[27]. In brief, tissue sections were deparaffinized, rehydrated, per-
meabilized in 20 Ìg/ml proteinase K in 10 mM tris, pH 8.0 and
blocked for endogenous peroxidases in 3% hydroxygen peroxide in
methanol. Slides were then labeled with TdT labeling reaction mix
and incubated for 1.5 h at 37°C. Signal was amplified using the
ABC-Elite reagent (Vector) and visualized with 3,3)-diaminobenzi-
dine and nickel enhancement. Counterstaining was performed with
periodic acid-Schiff/methyl green dyes.
Electron Microscopy
Randomly selected cases of hyperlipidemic and hyperglycemic
mice were utilized for transmission electron microscopy. The proto-
col for tissue preparation and staining has been described previously
[28]. Grids were scanned using a Philips 410 electron microscope
(Philips, Eindhoven, The Netherlands).
Quantitative Analysis and Statistics
Morphometric analysis was performed on HE and PAM stained
kidney sections. Fifteen random glomerular cross-sections were pho-
tographed by an examiner blinded for the origin of the sample using a
digital camera (Olympus DP11, Olympus America, Melville, N.Y.,
USA). The images were imported into the Image Pro Plus software
(Media Cybernetics, Silver Spring, Md., USA) and the number of
nuclei, the amount of mesangial matrix and the glomerular tuft area
were quantified. The number of macrophages and PCNA-positive
cells was counted in at least 40 glomerular cross section or high power
fields per slide. Glomerular ·-smooth muscle actin expression in
mesangial areas was assessed semi-quantitatively on a scale from 0
(negative) to 4 (strong expression in the whole mesangium) as pre-
viously described [29].
Statistical differences were assessed using the SPSS program
(SPSS Inc., Chicago, Ill., USA). Values are expressed as mean B
SEM. Groups were compared using ANOVA with Tukey’s posthoc
test. p ! 0.05 was considered statistically significant.
Results
Plasma Cholesterol, Triglycerides and Blood Glucose
Levels
Total cholesterol levels were measured in mice of the
different experimental groups. LDL receptor deficiency
in BALB mice alone led to a modest increase in plasma
cholesterol content, but values did not reach levels of sta-
tistical significance. In contrast, total cholesterol levels
increased threefold in BALB.LDLR–/– animals fed the
Western diet as compared to chow fed BALB.LDLR–/–
mice, and increased further when mice were made diabet-
ic with STZ treatment (table 1). Serum triglyceride levels
were not significantly different in the different experi-
mental groups.
STZ treatment of wild-type and BALB.LDLR–/– mice
led to a strong increase in blood glucose from 78 mg/dl
(control mice) to over 300 mg/dl in treatment groups
(BALB, STZ 396 B 76 mg/dl; BALB, STZ, Western diet
343 B 83 mg/dl; BALB.LDLR–/–, STZ, Western diet
471 B 79 mg/dl). However, STZ treated, chow fed
BALB.LDLR–/– mice had only slightly elevated glucose
levels of 180 B 21 mg/dl. This was most likely due to a
commercial lot of STZ with lower potency or variability
in individual responsiveness to STZ.
Hyperlipidemia and Hyperglycemia Act
Synergistically to Induce Glomerular Pathology in
BALB Mice
During the time course of this study (10 weeks of West-
ern diet and 12 weeks of hyperglycemia) glomerular mor-
phology was only modestly altered by either hyperglyce-
mia or hyperlipidemia alone. BALB.LDLR–/– mice did
Renal Pathology in Diabetic
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Table 1. Plasma levels for cholesterol,
triglycerides, blood glucose and blood urea
nitrogen
Cholesterol
mg/dl
Triglycerides
mg/dl
Blood glucose
mg/dl
BUN
mg/dl
1
BALB
Chow
81B9
* vs. 6
** vs. 8
104B18 78B7
** vs. 8
22B2
** vs. 7
*** vs. 8
2
BALB
Western diet
174B10
** vs. 8
104B22 141B11
** vs. 8
22B3
** vs. 7
*** vs. 8
3
BALB
Chow
STZ
148B30
** vs. 8
163B16 396B76 36B4
** vs. 8
4
BALB
Western diet
STZ
139B23
* vs. 6
*** vs. 8
109B22 344B83 32B4
*** vs. 8
5
BALB.LDLR–/–
Chow
193B25
** vs. 8
170B19 122B11
** vs. 8
36B3
** vs. 8
6
BALB.LDLR–/–
Western diet
572B29
* vs. 1, 4
180B22 141B4
*** vs. 8
30B4
* vs. 7
*** vs. 8
7
BALB.LDLR–/–
Chow
STZ
227B14
** vs. 8
238B32 180B21
* vs. 8
51B8
* vs. 6
** vs. 1, 2
8
BALB.LDLR–/–
Western diet
STZ
724B132
** vs. 1, 2, 3, 5, 7
*** vs. 4
558B190 471B79
** vs. 1, 2, 5, 7
*** vs. 6
69B4
** vs. 3, 5
*** vs. 1, 2, 4, 6
Values are expressed as mean B standard error of the mean. Significant differences
expressed as * p ! 0.05, ** p ! 0.01, *** p ! 0.001.
not display remarkable changes in glomerular architec-
ture. Glomeruli from BALB.LDLR–/– animals fed a
Western diet (hyperlipidemic mice) showed occasional
foam cells and fat droplets in the mesangium. Overall glo-
merular cellularity was not altered and matrix was only
slightly, but not significantly, increased. Wild-type mice
treated with STZ to induce hyperglycemia showed a small
increase in glomerular cellularity (45.7 B 3.4 cells/glo-
merular cross-section (gcs) for diabetic mice vs. 39.7 B
2.0 cells/gcs in wild type controls) and matrix (241.8 B
30.1 Ìm2 in mice made diabetic vs. 139.3 B 26.1 Ìm2 in
BALB control animals), both not significantly different
from wild type controls (fig. 1, 2). In contrast, animals
whose kidneys were exposed to both hyperlipidemia and
hyperglycemia together showed an increase in glomerular
cell number (59.8 B 2.5 cells/gcs vs. 39.7 B 2.4 in chow-
fed BALB mice, p ! 0.001; fig. 1). In addition, hyperlipi-
demic BALB.LDLR–/– mice with STZ-induced hypergly-
cemia also demonstrated a significant increase in glomer-
ular matrix compared to diabetic control animals (423 B
24 vs. 242 B 30 Ìm2, p ! 0.001; fig. 2). Both increased
glomerular cellularity and matrix led to the expansion of
the glomerular tuft area from 2,546 B 208 Ìm2 in control
animals to 4,440 B 145 Ìm2 in hyperglycemic BALB.
LDLR–/– mice fed the Western diet (p ! 0.001). The glo-
meruli of these mice were frequently infiltrated with foam
cells and the mesangium commonly showed fat deposits
(fig. 3). However, neither mesangiolysis nor extensive fo-
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Fig. 1. Cell number per glomerular cross-section in experimental
groups expressed as mean B SEM. BALB.LDLR–/– mice on a West-
ern diet with STZ-induced diabetes are significantly different from
BALB controls on chow at a level of *** p ! 0.001 and significantly
different from BALB.LDLR–/– controls on chow and BALB control
mice on a Western diet at a level of ** p ! 0.01.
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Fig. 2. Extracellular matrix per glomerular cross section in experi-
mental groups, expressed as mean B SEM. Significant differences
between diabetic BALB.LDLR–/– mice on Western diet and diabetic
BALB mice on a Western diet at a level of * p ! 0.05 and between
diabetic BALB.LDLR–/– mice on Western diet and chow fed BALB
controls, chow fed BALB.LDLR–/– mice, BALB and BALB.
LDLR–/– on a Western diet as well as chow-fed diabetic BALB mice
at a level of *** p ! 0.001. Chow-fed BALB control mice show signif-
icantly less glomerular matrix than their diabetic and hyperlipidemic
counterparts.
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Fig. 3. Glomerular architecture, periodic
acid methenamine silver stain. A Normal
glomerular structures in BALB control mice.
B BALB mouse, STZ treatment leads to
slight increase in extracellular matrix and
mild hypercellularity. C Normal glomerular
architecture of a BALB.LDLR–/– mouse,
fed a Western diet. D BALB.LDL receptor
knockout mouse, Western diet, STZ treat-
ment. The arrows point to foam cells, arrow-
heads indicate mesangial lipid deposits. The
glomerulus shows an increase in glomerular
matrix and hypercellularity.
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Table 2. Glomerular features
Macrophages/
gcs
Proliferating
cells/gcs
(PCNA)
·-Smooth
muscle actin
expression/gcs
1
BALB
Chow
0.3B0.3 1.6B0.3 0.1B0.0
2
BALB
Western diet
0.4B0.1 1.5B0.3 0.1B0.0
3
BALB
Chow
STZ
0.4B0.1 1.2B0.4 0.1B0.0
4
BALB
Western diet
STZ
0.5B0.1 1.7B0.3 0.2B0.0
5
BALB.LDLR–/–
Chow
0.2B0.1 1.3B0.2 0.2B0.2
6
BALB.LDLR–/–
Western diet
0.4B0.1 2.1B0.2 0.1B0.0
7
BALB.LDLR–/–
Chow
STZ
0.4B0.1 1.8B0.2 0.1B0.0
8
BALB.LDLR–/–
Western diet
STZ
1.9B0.2
***, ###
1.7B0.3 0.1B0.0
Values are expressed as mean B standard error of the mean. Sig-
nificant differences compared to BALB controls on chow (1): *** p !
0.001; significant differences compared to diabetic controls (3):
### p ! 0.001.
cal segmental sclerosis was noted and there was no
increase in glomerular expression of ·-smooth muscle
actin in any of the experimental groups (table 2).
Glomeruli from control mice, BALB.LDLR–/– mice
fed the Western diet or hyperglycemic STZ-treated mice
were only occasionally infiltrated with macrophages (ta-
ble 2). In contrast, hyperglycemic and hyperlipidemic
BALB.LDLR–/– mice had significantly increased num-
bers of glomerular macrophages (1.9 B 0.2/gcs) compared
to BALB mice (0.3 B 0.3/gcs, p ! 0.001), as well as BALB
mice that were treated with STZ (0.4 B 0.1/gcs, p ! 0.001)
or hyperlipidemic BALB.LDLR–/– mice (0.4 B 0.1/gcs,
p ! 0.001) (table 2; fig. 4). Glomerular proliferation was at
a low level in all experimental groups with only occasional
positive staining for the proliferation marker PCNA and
remained unaltered by the induction of diabetes mellitus
or hyperlipidemia either alone or in combination. The
extent of glomerular cell death, as assessed by TUNEL
staining, revealed no differences between experimental
groups.
Hyperlipidemic BALB.LDLR–/– Mice with
STZ- Induced Diabetes Mellitus Show Prominent
Tubulointerstitial Damage
While BALB.LDLR–/– mice fed rodent chow did not
show significant tubular or interstitial pathology, mice fed
the Western diet, leading to significant hyperlipidemia,
demonstrated some lipid deposition in tubular epithelial
cells. Occasionally, interstitial foam cells were seen. Dia-
betic BALB mice had no remarkable tubulointerstitial
changes. In contrast, hyperglycemic BALB.LDLR–/– ani-
mals fed the Western diet showed a high degree of tubular
degeneration, with large amounts of lipids deposited in
the tubular epithelial cells. Foam cells were frequently
present in the interstitium. Interstitial macrophage influx,
assessed as mac-2 positive cells per 20! high power field,
was also increased in these mice compared to normogly-
cemic (7.5 B 0.9/field vs. 2.6 B 0.6/field, p ! 0.01) and
hyperglycemic BALB control mice (7.5 B 0.9/field vs. 2.7
B 1.1/field, p ! 0.01) (table 3).
Tubulointerstitial fibrosis, as it is seen in later stages of
human diabetic nephropathy, was not present in these
mice at the early timepoint studied and no significant
interstitial cell expression of · smooth muscle actin was
noted in any of the study animals.
Similarly, neither hyperlipidemia nor hyperglycemia
alone significantly influenced tubulointerstitial cell prolif-
eration. However, tubulointerstitial proliferation was sig-
nificantly increased in combined diabetic and hyperlip-
idemic BALB.LDLR–/– mice compared to mice that were
only hyperglycemic (14.2 B 2.0 cells/20! high power
field vs. 7.6 B 1.4 cells/20! high power field, p ! 0.05)
(table 3). Tubulointerstitial apoptotic cell death was also
increased in these animals (64.3 B 18.9 cells/20! high
power field vs. 12.5 B 3.8 cells/20! high power field,
p ! 0.01), while neither hyperlipidemia nor hyperglyce-
mia alone was able to induce significant amounts of apop-
tosis. Histological examination identified most prolifer-
ating and TUNEL positive cells as tubular epithelial
cells (fig. 5), indicating increased tubular cell turnover
(table 3).
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Fig. 4. A–D Glomeruli of experimental ani-
mals stained with PAS/methyl green. Immu-
nohistochemistry for macrophages (anti-
mac-2 stain) has been performed. A Glomer-
ulus of a chow-fed BALB mouse. B Example
of a typical glomerulus of a mouse made dia-
betic with STZ. C Slight increase in glomeru-
lar macrophage count in hyperlipidemic
BALB.LDLR–/– mice fed the Western diet.
D Strongly increased glomerular macro-
phage influx in BALB.LDLR–/– mice after
exposure to a Western diet and STZ-induced
hyperglycemia. Picture E shows strong in-
crease of interstitial macrophages/foam cells
in hyperglycemic BALB.LDLR–/– mice fed
the Western diet. Mac-2 immunohistochem-
istry with PAS/methyl green counterstain.
Combined Hyperlipidemia and Hyperglycemia Led to
a Reduction in Excretory Kidney Function in
BALB.LDLR–/– Mice
Feeding the Western diet or STZ treatment alone
resulted in only modest increases in plasma blood urea
nitrogen (BUN), which did not reach the level of statistical
significance when compared to controls. Excretory renal
function in hyperlipidemic BALB.LDLR–/– mice was also
not affected. However, both conditions together (Western
diet and STZ treatment in BALB.LDLR–/– mice) led to a
significant increase in plasma BUN values from 22 B 2 to
69 B 4 mg/dl (p ! 0.01; table 1) corresponding to the glo-
merular and tubulointerstitial pathology.
Electron Microscopy
Electron microscopy was performed on selected hyper-
glycemic BALB.LDLR–/– mice fed the Western diet.
Ultrastructural pathology in these animals was modest
with focal effacement of the podocyte foot processes and
focal loss of fenestration of glomerular endothelial cells
Renal Pathology in Diabetic
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Fig. 5. Tubular changes in hyperglycemic BALB.LDLR–/– mice fed the
Western diet. A ‘Foamy’ degeneration of tubular epithelial cells, asterisks
indicate interstitial foam cells. Periodic acid methenamine silver stain.
B Immunohistochemistry for PCNA (cellular proliferation marker), dark
nuclei represent positive cells, note also tubular degeneration in affected
area. C TUNEL staining for apoptotic cell death, dark nuclear staining indi-
cates apoptosis.
Table 3. Tubulointerstitial injury markers
Macrophages
(Mac-2)
Proliferating
cells (PCNA)
TUNEL-
positive cells
1
BALB
Chow
2.6B0.6 4.4B0.9 4.5B1.1
2
BALB
Western diet
2.6B0.7 5.7B1.2 7.1B1.2
3
BALB
Chow
STZ
2.7B1.1 7.6B1.4 12.5B3.8
4
BALB
Western diet
STZ
2.8B0.7 5.7B1.0 18.0B6.2
5
BALB.LDLR–/–
Chow
1.2B0.2 3.3B0.6 6.5B1.2
6
BALB.LDLR–/–
Western diet
1.9B0.5 4.4B0.4 10.4B1.9
7
BALB.LDLR–/–
Chow
STZ
4.1B0.9 5.4B0.7 21.6B5.2
8
BALB.LDLR–/–
Western diet
STZ
7.5B0.9
**, ##
14.2B2.0
***, #
64.3B18.9
**, ##
Values are expressed as mean B standard error of the mean. Sig-
nificant differences compared to BALB controls on chow (1): ** p !
0.01, *** p ! 0.001; significant differences compared to diabetic con-
trols on chow (3): # p ! 0.05, ## p ! 0.01.
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Fig. 6. Electron transmission microscopy of
the kidneys of selected hyperglycemic
BALB.LDLR–/– mice fed the Western diet.
A Glomerular capillary loop, arrow points to
endothelial cell changes with enlarged suben-
dothelial space. B Glomerular capillary loop,
arrow points to mesangial lipid drop, arrow-
heads indicate epithelial changes with ef-
facement of foot processes.
(fig. 6). Small droplets of lipids could occasionally be seen
in the mesangium. Similarly, tubular epithelial cells dis-
played intracellular lipids but little architectural altera-
tion. The tubular brush border and the basolateral cellular
interdigitations remained largely intact.
Discussion
We studied a newly created murine strain, the BALB.
LDLR–/– mouse, and subjected this strain to additional
stresses of exacerbated hyperlipidemia and hyperglyce-
mia in an attempt to develop a murine model of human
diabetic nephropathy that reproduced the key features of
this nephropathy better than other currently available
murine models. Under the combined stress of hyperlipid-
emia and hyperglycemia, these mice developed glomeru-
lar changes seen in early human diabetic nephropathy
including increases in cellularity and in mesangial extra-
cellular matrix. Additional renal injury, seemingly the
result of hyperlipidemia, but requiring hyperglycemia for
its full development, was present in the form of glomeru-
lar infiltration of fat droplets and foam cells, tubulointer-
stitial injury characterized by widespread tubular degen-
eration accompanied by increased turnover of tubular
epithelial cells and a significant increase in interstitial
macrophages/foam cells. These animals also showed sig-
nificantly elevated levels of blood urea nitrogen, indicat-
ing that the pathological changes lead to some degree of
renal functional impairment. These findings lead us to
consider that alterations of lipid metabolism may be
important for successful development of murine models
for diabetic nephropathy.
Hyperlipidemia is well established as a risk factor for
cardiovascular disease and has been suggested to contrib-
ute to renal injury. Although human studies have not been
able to demonstrate increased incidence of renal disease
in patients with dyslipidemia [30], there is evidence that it
may be a risk factor for the progression of preexisting
renal disease [31, 32]. The pathophysiologic mechanisms
by which hyperlipidemia exerts its harmful effects on the
kidney are still poorly understood.
One possibility is direct injury by lipids and lipopro-
teins. The kidney, both glomeruli and the tubulointersti-
tium, may be a preferred location for lipid deposition in
hyperlipidemic states because of the presence of fenes-
trated endothelium in glomerular and peritubular capil-
laries, increasing the accessibility of these locations for
circulating lipids. In vitro studies have demonstrated that
circulating plasma lipoproteins can be trapped in the glo-
meruli where they bind to extracellular matrix [33]. There
they can either be taken up by resident mesangial cells
[34], or endocytosed by monocytes/macrophages, which
then become foam cells. Studies have also established that
mesangial cells are able to oxidize lipoproteins and endo-
cytose them via a specific scavenger receptor [33, 35]. In
vitro exposure of mesangial cells to lipoproteins leads to
increased cellular proliferation rates [34, 36, 37]. Lipopro-
teins can also induce the release of cytokines, like TGF-ß
and PDGF [36, 38] and increase the expression of che-
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moattractants like m-CSF and MCP-1 by mesangium
cells [39–41]. LDL has also been found to promote in
vitro mRNA expression of collagen IV and fibronectin,
major components of the extracellular matrix [41, 42].
Our studies indicate a synergistic effect of hyperlipidemia
to glomerular injury of hyperglycemia, but do not define
the specific pathways by which this occurs.
A second possibility by which hyperlipidemia pro-
motes renal injury involves a primary role for macro-
phages as mediators of non-immune glomerular injury.
The involvement of macrophages in the development of
lipid-induced nephropathy has been emphasized in renal
injury either induced by diets rich in cholesterol or by
genetic predisposition [10, 11, 43]. Dietary hypercholes-
terolemia has been shown to induce glomerular macro-
phage influx in rats, while hypertriglyceridemia had no
corresponding influence on the amount of macrophages
present in the glomeruli [11]. The obese Zucker rat, a
strain where the mutation in the fa gene leads to hyper-
phagia associated with obesity, hyperlipidemia, and later,
impaired glucose tolerance through increased peripheral
insulin resistance, demonstrates an early increase in glo-
merular monocyte/macrophage influx at the age of 6
weeks, well before any other renal changes can be detected
and at a time point when blood glucose levels are still
unaltered [44]. In accordance with this data, our study
demonstrates increased influx of macrophages and foam
cells into glomeruli of hyperlipidemic, hyperglycemic
mice compared to glomeruli of mice that were exposed to
only one of these factors. The relevance of these macro-
phages is suggested by studies that indicate that macro-
phages in hyperlipidemic nephropathy can lead to an
increase in glomerular TGF-ß and fibronectin expression
[43, 45], and that the involvement of macrophages in ear-
ly renal injury of STZ-induced diabetes mellitus (8 days
after induction of hyperglycemia) leads to an increase in
glomerular collagen IV mRNA that could be reduced, but
not completely reversed, by insulin treatment or irradia-
tion-induced depletion of macrophages [46]. Thus, the
local accumulation of macrophages, although not charac-
teristic of morphologically advanced diabetic nephropa-
thy in humans, may act synergistically with hyperglycem-
ia by secreting growth factors and cytokines to induce
fibrotic processes that may be important early in the
development of the disease. This scenario is supported by
the results of our study that show increased extracellular
matrix in the glomeruli of hyperlipidemic and hypergly-
cemic mice.
Although the most distinctive features of diabetic ne-
phropathy occur in the glomeruli, tubulointerstitial
changes represent a major aspect of chronic diabetic renal
disease. It is now well accepted that chronic tubulointer-
stitial injury including interstitial infiltration of mononu-
clear cells and interstitial fibrosis is the major determi-
nant for the progression of renal disease [47]. Studies in
human biopsies have shown that the decline in renal func-
tion correlates most closely with changes in the tubules
and the interstitium, rather than in the glomeruli [48, 49].
STZ-induced diabetes mellitus, the most widespread ani-
mal model for type I diabetes, does not lead to significant
changes in the tubulointerstitium and does not progress to
renal insufficiency, rendering this model less than satis-
factory as an experimental model for human diabetic
nephropathy. In this study, we attempted to model hu-
man diabetic pathology more closely by adding a second
risk factor for the development of kidney disease to an
established model of experimental diabetes mellitus. We
were able to demonstrate significant tubular injury in
hyperlipidemic BALB.LDLR–/– knockout mice made di-
abetic with STZ and fed the high-fat Western diet. Patho-
logic changes included prominent lipid deposition in
tubular epithelial cells, increased influx of monocytes/
macrophages into the tubulointerstitium and increased
proliferation of tubular epithelial cells. The high prolifera-
tion rates were accompanied by high levels of apoptotic
cells in the tubules of affected animals. Limited amounts
of tubular cell apoptosis have been described in STZ-
induced diabetic nephropathy later in the disease at 24
weeks [50], but mice in our study demonstrated only very
limited apoptotic cell death in the tubulointerstitium after
12 weeks of hyperglycemia. It would appear that the pro-
apoptotic effect of hyperglycemia on renal tubules ob-
served by us and others may be aggravated by the addi-
tional damaging effect of increased tubular lipid accumu-
lation as shown in our hyperlipidemic, hyperglycemic
mice. The consequence of this tubular injury is not clear,
as these mice did not develop significant interstitial fibro-
sis after 10 weeks of experiencing both hyperglycemia and
hyperlipidemia. Long time frames for the development of
the fibrosing injury may be required, as it is for human
diabetic nephropathy.
In summary, our results indicate that hyperlipidemia
and hyperglycemia act synergistically in inducing renal
injury. This is consistent with the situation in humans, in
which patients with primary hyperlipidemia have no
clearly defined increased incidence of renal disease, but
in whom lipids may act synergistically in the initiation
and progression of diabetic nephropathy [51]. BALB.
LDLR–/– mice represent a new model to study the inter-
action between STZ-induced diabetes mellitus and hyper-
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lipidemia [52]. These mice demonstrate the characteristic
glomerular changes of murine diabetic nephropathy but
have the additive feature of tubular pathology. We believe
this model of diabetic nephropathy in a hyperlipidemic
mouse strain may be a useful tool to address the function-
al impact of both factors on the kidney, but additional
model development is required to produce the character-
istic microvascular and arteriolar injury of human diabet-
ic nephropathy in mice.
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